Advancing the World of Health

BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and OUR PURPOSE: evolving health needs. Advancing the world of health

MORE THAN OUR FOCUS:

ENABLING safer, simpler and more effective drug delivery

45,000 IMPROVING outcomes ASSOCIATES SERVING through more accurate, timely and efficient diagnostics

PROVIDING tools and Advancing the technologies to the research community that facilitate the world of health understanding of the cell, cellular diagnostics and cell therapy 190+ ENHANCING disease management in diabetes, COUNTRIES women’s health and cancer, and infection control 2015 ANNUAL REPORT 1 BECTON DRIVE ADVANCING clinical, FRANKLIN LAKES, NJ 07417 IN 2015, BD welcomed laboratory and research WWW.BD.COM CareFusion and its practices in emerging markets products into the BD family of solutions. For more information on BD, please visit www.bd.com.

FRONT COVER - 8.75 x 11.25 GATEFOLD - 8.5 x 11.25 Design by Addison www.addison.com Addison by Design

members of the Paper Task Force. Task Paper the of members

other and Fund Defense Environmental

by research on based Calculations Source: *

energy not consumed not energy please visit www.bd.com/sustainability2014. visit please

11,500,000 BTUs 11,500,000

Program and our 2020 Sustainability Goals, Goals, Sustainability 2020 our and Program

For information about BD’s Sustainability Sustainability BD’s about information For

greenhouse gases prevented gases greenhouse

22,181 lbs net lbs 22,181

certified renewable energy certificates. energy renewable certified Green-e

manufactured with electricity that is offset with with offset is that electricity with manufactured

solid waste not generated not waste solid

and and is designated Ancient Forest Friendly Forest Ancient designated is

8,053 lbs 8,053 TM

an average of 100% post-consumer waste. It It waste. post-consumer 100% of average an

with an average of 100% recycled fiber and and fiber recycled 100% of average an with wastewater flow saved flow wastewater

120,300 gal 120,300 25,736 pounds of Reincarnation Silk 100, made made 100, Silk Reincarnation of pounds 25,736

BD saved the following resources by using using by resources following the saved BD

trees preserved for the future the for preserved trees

258 PRINTING INFORMATION* PRINTING BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and OUR PURPOSE: evolving health needs. Advancing the world of health

MORE THAN OUR FOCUS:

ENABLING safer, simpler and more effective drug delivery

45,000 IMPROVING outcomes ASSOCIATES SERVING through more accurate, timely and efficient diagnostics

FRONT COVER - 8.75 x 11.25 GATEFOLD - 8.5 x 11.25 Design by Addison www.addison.com Addison by Design

members of the Paper Task Force. Task Paper the of members

other and Fund Defense Environmental

by research on based Calculations Source: *

energy not consumed not energy please visit www.bd.com/sustainability2014. visit please

11,500,000 BTUs 11,500,000

Program and our 2020 Sustainability Goals, Goals, Sustainability 2020 our and Program

For information about BD’s Sustainability Sustainability BD’s about information For

greenhouse gases prevented gases greenhouse

22,181 lbs net lbs 22,181

certified renewable energy certificates. energy renewable certified Green-e

manufactured with electricity that is offset with with offset is that electricity with manufactured

solid waste not generated not waste solid

and and is designated Ancient Forest Friendly Forest Ancient designated is

8,053 lbs 8,053 TM

an average of 100% post-consumer waste. It It waste. post-consumer 100% of average an

with an average of 100% recycled fiber and and fiber recycled 100% of average an with wastewater flow saved flow wastewater

120,300 gal 120,300 25,736 pounds of Reincarnation Silk 100, made made 100, Silk Reincarnation of pounds 25,736

BD saved the following resources by using using by resources following the saved BD

trees preserved for the future the for preserved trees

258 PRINTING INFORMATION* PRINTING Vincent A. Forlenza Chairman, Chief Executive Officer and President

TO OUR SHAREHOLDERS: During this transformative year, we reposi- healthcare company. Our teams were tioned BD as a global leader in medication charged with more than just identifying By all measures, fiscal management and healthcare safety solu- synergy opportunities; they also had to 2015 was a historic tions with the $12 billion acquisition of challenge themselves to transform the CareFusion. Combining with CareFusion organization and how we work. We made year for BD, unlike any advances our strategy to deliver end- integrating cultures a top priority, reartic- other in our 118-year to-end solutions that increase efficiency, ulating our company purpose to reflect history. It has been my reduce medication errors and improve our leadership role in Advancing the world both healthcare worker and patient safety of health. We also refreshed our brand distinct pleasure and across all healthcare settings. At the same identity and introduced a new set of privilege to be at the time, we entered the genomics space with value statements to reflect the strengths helm as we evolve into the acquisitions of GenCell Biosystems and beliefs of both legacy organizations. and Cellular Research combined with our Our merger doubled the size of the BD a bigger, better and more than 30 years of experience in Medical segment during the year, and bolder company — cell-sorting technologies. We’re seeking as a combined company, we became to improve the sample management a “New BD” that will a leader in the $20 billion medication process in the fast-growing arena of next management space. With this strong be stronger and generation sequencing (NGS) by helping foundation in place, we’ve been able to customers increase workflow efficiency, more relevant than make significant progress integrating improve outcomes and reduce costs. ever before. CareFusion and BD. We are creating The underlying principle that guided end-to-end solutions across the care con- our CareFusion integration efforts was tinuum — from the hospital, to alternate as simple as it was ambitious: to focus care and retail settings, to the home — to our work on creating a new and better improve healthcare efficiency, quality

BD 2015 ANNUAL REPORT 1 Advancing the world of health The New BD — structured to serve customers with unique solutions

ChloraPrep® Skin Antiseptic

BD MEDICAL ChloraPrep® Skin Antiseptic Pyxis MedStation® ES System BD Eclipse™ Needle REDUCE the spread Hospitals and Diabetes Care BD Intelliport™ Medication of infection Management System clinics Medication ENHANCE Physicians Management BD Cato™ Medication diabetes Workflow Solution Solutions treatment Government and ® public health Pyxis MedStation ADVANCE Medication ES System agencies drug delivery Alaris® System and Procedural ® System Healthcare workers Solutions Alaris IMPROVE respiratory care Retail pharmacies BD Nano™ 4mm Pharmaceutical and surgical BUSINESSES Pen Needle Pharmaceutical Systems procedures BD AutoShield Duo™ Pen Needle and biotech BD AutoShield Duo™

Pen Needle PROVIDE companies

Respiratory CUSTOMERS SERVING effective and DELIVERING OUTCOMES DELIVERING Solutions OFFERINGSINNOVATIVE Consumers BD Hypak™ Glass safe medication Prefillable Syringes management

AVEA® Ventilators PRINTING INFORMATION* 258 trees preserved for the future BD Physioject™ Disposable BD saved the following resources by using Autoinjector 25,736 pounds of Reincarnation Silk 100, made 120,300 gal with an average of 100% recycled fiber and wastewater flow saved BD LIFE SCIENCES BD Vacutainer® Push ADVANCE Research, clinic, an average of 100% post-consumer waste. It Button Blood Collection Set the science and industrial and is designated Ancient Forest FriendlyTM and 8,053 lbs applications solid waste not generated ® reference laboratories BD Vacutainer® manufactured with electricity that is offset with BD Vacutainer Blood associated with Collection Tubes Blood Collection Tubes Green-e® certified renewable energy certificates. cellular analysis Blood banks 22,181 lbs net greenhouse gases prevented Biosciences Laboratory For information about BD’s Sustainability BD Kiestra™ Hospitals and clinics Automation IMPROVE Program and our 2020 Sustainability Goals, 11,500,000 BTUs lab efficiency please visit www.bd.com/sustainability2014. Diagnostic Alternate site energy not consumed System and outcomes Systems BD Veritor™ healthcare from sample * Source: Calculations based on research by BD MAX™ System collection to Environmental Defense Fund and other Preanalytical Public health agencies members of the Paper Task Force. diagnostic result Systems BD FACSPresto™ BD FACSAria™ Fusion Flow

BUSINESSES Academic and Cytometer Near-Patient CD4 Counter ENHANCE government infectious institutions BD Horizon Brilliant™

disease CUSTOMERS SERVING

DELIVERING OUTCOMES DELIVERING Pharmaceutical and INNOVATIVE OFFERINGSINNOVATIVE BD LSRFortessa™ X-20 diagnosis and BD Kiestra™ Laboratory Automation Cell Analyzer management biotech companies Design by Addison www.addison.com

GATEFOLD - 8.5 x 11.25 IFC The New BD — structured to serve customers with unique solutions

ChloraPrep® Skin Antiseptic

Pen Needle PROVIDE companies

Respiratory CUSTOMERS SERVING effective and DELIVERING OUTCOMES DELIVERING Solutions OFFERINGSINNOVATIVE Consumers BD Hypak™ Glass safe medication Prefillable Syringes management

BUSINESSES Academic and Cytometer Near-Patient CD4 Counter ENHANCE government infectious institutions BD Horizon Brilliant™

disease CUSTOMERS SERVING

GATEFOLD - 8.5 x 11.25 IFC and outcomes. During the year, we also With our progress in fiscal 2015 and our advanced our chronic disease manage- growth strategies for fiscal 2016 and ment strategy, expanding our impact in beyond, we are very well positioned to diabetes management beyond products become a more customer-centric pro- for insulin injection. vider of world-class, quality, innovative healthcare products and solutions — While much of the spotlight this past a company focused on increasing access, year was on the BD Medical segment as improving outcomes, mitigating health- a result of the CareFusion acquisition, care system cost pressures and protecting we also made strategic investments in patients and healthcare workers. While our BD Life Sciences segment, which we continue to expand our leadership remains an important growth driver for and relevance in the spaces, care settings BD as we aim to improve lab efficiency and geographies that we have served so and outcomes from sample to diagnos- BD’s global footprint, scale well for so long, we are also beginning to tic result. We believe our GenCell and extend into emerging areas — including and infrastructure creates Cellular Research portfolio additions — in digital health and single cell genomics, even more opportunity combination with our robust innovation and adjacent care settings across the pipeline and our experience developing for our businesses around patient care continuum — to ensure we research-to-clinical applications — puts us are well aligned as our dynamic industry the world. well on the path toward “democratizing” continues to evolve. NGS by improving workflow efficiency and outcomes and driving down costs in the sample management process.

REVENUE(1) BY REGION (billions of dollars) $ $ 2.4 5 .1 EUROPE UNITED STATES

GREATER ASIA $1.2 $1.5 OTHER(2)

(1) Values in this exhibit reflect rounded numbers. (2) Other comprises Canada, Latin America, and EMA (which includes the Commonwealth of Independent States, Middle East and Africa). REVENUE(1) BY SEGMENT $1.0 Diabetes Care (billions of dollars) $1.0 Medication Management Solutions

$2.9 Medication and Procedural Solutions Biosciences $1.1 $ Pharmaceutical $ $ 1.2 Diagnostic 1.3 10.3 Systems Systems TOTAL $ Respiratory $ 0.4 Preanalytical 1.4 REVENUE Solutions Systems

$3.8 $6.5 BD LIFE BD MEDICAL SCIENCES

(1) Values in this exhibit reflect rounded numbers.

OUR VALUES FINANCIAL HIGHLIGHTS developed markets, we will continue to see more balanced top-line contributions Overall, our financial results for fiscal We do what is right from the U.S. and international markets 2015 were very strong, closing out a his- going forward. Although emerging toric year for BD. We exceeded $10 billion We take personal markets will represent a lower percentage in revenues, driven primarily by the addi- of overall company revenues, we responsibility tion of the CareFusion portfolio during continue to invest in these higher-growth the second half of the fiscal year and areas and are working to create new We anticipate and solid performance in our core businesses. growth opportunities for CareFusion Including the results of CareFusion in address the challenges products in these markets by leveraging both the current- and prior-year periods, the BD international infrastructure. of patients and our revenues increased in line with our customers globally long-term goal of delivering top-line Our strong top-line growth carried growth in the mid-single digits annually. through to the bottom line as our adjusted We innovate and diluted earnings per share exceeded These results also reflected the benefit our guidance range for the year. This improve continuously of our diverse geographic and product was due, in part, to merger-related cost portfolio, as we saw solid contributions savings. Through the tremendous work We respect, collaborate, from both the BD Medical and BD Life of our functional integration teams, we Sciences segments as well as our global challenge and care exceeded our internal cost-savings tar- markets. We delivered strong growth in about each other gets for the first year of the CareFusion the U.S. region, and because CareFusion merger. We now expect to deliver between revenues are predominantly derived from $325 million and $350 million in cost

BD 2015 ANNUAL REPORT 2 3/ 3 Advancing the world of health savings by fiscal 2018, up from our earlier our business and geographic diversity, our the year, we reinvested more than target of $250 million. balanced capital allocation and focus on 6 percent of revenues in R&D, funding the efficiency provides a long-term pathway development of new products that we Further, we demonstrated a balanced toward sustainable, profitable growth. believe will help us drive and sustain our approach to capital deployment in fiscal growth over the long term. We entered 2015. We paid off $1 billion in debt used DRIVING GROWTH the fiscal year with more products in our to partially fund the CareFusion acquisi- THROUGH INNOVATION pipeline than ever before and expect to tion and increased our dividend for the launch more than 15 new products in 43rd consecutive year. We will balance BD continued to focus on innovation fiscal 2016 alone. the investments we make in organic and in fiscal 2015 to drive future financial inorganic growth opportunities and in performance and growth. The combined In recognition of our sustained efforts efficiency improvements with our tar- efforts of our internal teams and our to create a culture of innovation, BD was geted leverage goals while increasing our external strategic partners and alliances honored by the Product Development dividend in line with long-term earnings helped us to build a pipeline of new, and Management Association with its growth. We believe the combination of clinically differentiated products. During prestigious 2015 Outstanding Corporate

ADVANCING BD became the global leader in the $20 billion MEDICATION medication management industry with the MANAGEMENT acquisition of CareFusion. The new extended portfolio of products provides a complete end-to-end solution from pharmacy to patient.

Using the CAREFUSION AN APY M AGEM ER EN SMARTWORKS PLATFORM TH T as the communication backbone DOCUMENT PROCURE between our solutions and Health IT ONITOR systems, BD offers a safer and more M efficient way to procure, store, prep,

ADMINISTER PICK T

track, dispense, administer and analyze M

E O medications across a health system D

A P

D and the entire continuum of care. Patient U H S

E The platform leverages innovative DISPENSE R N PREP O E I N S technologies including BD Cato™ CE CI DE Medication Workflow Solutions for safer and more efficient drug preparation, TRACK CHECK the Pyxis® ES system for enterprise medication dispensing, the Alaris® System for safe IV and advanced analytics that C s are ork provide decision support and medication Fusion SmartW adherence capabilities. ADVANCING BD Life Sciences is entering the high-growth GENOMICS AND genomics area through internal developments combined with strategic acquisitions. Our LABORATORY differentiated platforms create a base to further PRODUCTIVITY grow our genomics offering, leaving BD well- positioned to add long-term value by providing researchers and clinicians leading technologies that are efficient, scalable, high quality and cost effective.

BD is launching its first dedicated solu- combination enables thousands of tion specifically for single cell genomics cells to be analyzed accurately, quickly, applications with BD FACSseq™ easily and affordably. Understanding CELL SORTER, a high-through- the genomic differences of individual put cell sorter designed for single cell cell types provides unique insights into genomic studies, combined with B D disease characteristics that have the PRECISE™ ASSAYS for single potential to identify new approaches for cell gene expression analysis. The developing targeted therapies.

Innovator Award. This recognition We will continue our track record of Such endeavors earned BD a spot on validates our efforts over the past five shared-value creation, seeking out oppor- FORTUNE magazine’s first-ever “Change years to improve the efficiency and tunities to serve unmet societal needs the World” list, which acknowledges effectiveness of our R&D programs and through business models and initiatives companies that make a sizable impact on to transform our product development that also contribute to our commercial major social or environmental problems system, processes and approach to drive success. We embrace the opportunity as part of their competitive strategy. For commercial excellence and better deliver to make a meaningful difference in the me, this recognition is a testament to the on market and customer needs in align- lives of others and in the communities unique — and rewarding — opportunity ment with our global growth strategies. we call home. This year marked the 10th our associates have as part of BD, where anniversary of the BD Volunteer Service employees can fulfill their life’s work PURSUING OUR PURPOSE Trip, a unique opportunity that pairs BD through their work life. volunteers with selected healthcare orga- While much is changing at BD, the core nizations and programs that serve at-risk CONCLUSION of who we are and what we stand for has populations. Over the past decade, more not wavered. Our purpose — Advancing As we look forward, the prospects for than 110 volunteers have been deployed the world of health — highlights our the New BD are stronger than ever. Our to 20 countries to share their compassion expanded role as an industry leader and diversified Medical and Life Sciences and expertise to help strengthen local reinforces our commitment and ability to segments offer clinically differentiated healthcare services and improve the improve healthcare around the globe. products and innovative solutions overall quality of life and health for the that span discovery and delivery and people they serve.

BD 2015 ANNUAL REPORT 4 5/ 5 Advancing the world of health anticipate and address our customers’ end of March 2016 to ensure a successful personal knowledge of BD, has made him and healthcare systems’ most pressing transition of his integration duties to Chris an invaluable resource to the company. challenges. Our global footprint, scale and Reidy, our Executive Vice President, Chief While I’m proud of the many accomplish- infrastructure create even more oppor- Financial Officer, and Chief Administrative ments we achieved this past year, I’m tunity for BD to help increase healthcare Officer. Bill has demonstrated a relentless more excited about the future — about access and improve outcomes. We are commitment to operational excellence the potential developing within BD, the guided by a clear strategy grounded in to our customers and associates and has opportunities to reshape and redefine customer needs, a renewed purpose, a had a profound influence on us all. I want our industry and the positive impact we strong commitment to our values and to express my gratitude for his leadership can have Advancing the world of health. a refreshed brand identity that signals our as well as my congratulations on his transformation to a bigger, better, bolder reaching this key milestone. I look forward to sharing this journey with BD is firmly underway. you and want to thank you for your ongo- I also want to extend my personal thanks ing support and investment in BD. There are many people who deserve to two of our Board members — Henry thanks for this incredible year, especially Becton, Jr. and Edward DeGraan — who Sincerely, the 45,000 associates around the world are retiring following the 2016 Annual who are pulling together to create the Meeting. Ed is stepping down after New BD. Chief among them is Bill Kozy, 12 years of dedicated service, during our Executive Vice President and Chief which he provided valuable leadership to Vincent A. Forlenza Operating Officer, whom I want to thank management and the Board in a number Chairman, Chief Executive Officer for the exemplary work he and his team of areas. Henry has served on the Board and President are doing to lead the successful integra- since 1987 and is transitioning to the tion of CareFusion and BD. After 41 years role of Director Emeritus following the with BD, Bill has announced his retire- 2016 Annual Meeting. His broad business ment. He will stay with us through the background, coupled with his extensive

2015 AWARDS, RECOGNITIONS AND AFFILIATIONS

* 2015 THOMSON REUTERS TOP 100 GLOBAL INNOVATORS

Dow Jones Sustainability North Top Employers Africa 2015 — Practice Greenhealth — Champion for America Index, since 2005 Top Employers Institute Change Environmental Excellence

FORTUNE — “Change the World” Best Places for Women & Diverse U.S. EPA Green Power List 2015 Managers to Work — Diversity MBA Leadership Award 50 Out Front for Diversity Leadership Center for Political U.S. EPA SmartWay® Accountability — Top Leader in Work-Life Seal of Distinction — Transport Partner — Member Disclosure and Accountability 2015 WorldatWorks’s Alliance for Work-Life Progress® Windmade™ — Pioneer Company CEO Cancer Gold Standard™ Accreditation FTSE4Good Index, since 2003

*FORTUNE is a registered trademark of Time Inc. and is used under license. From FORTUNE Magazine © 2015 Time Inc. FORTUNE and Time Inc. are not affiliated with, and do not endorse products or services of, Licensee. CORPORATE INFORMATION

ANNUAL MEETING by calling Computershare Trust Securities and Exchange Commission Tuesday, January 26, 2016 – 1:00 p.m. Company, N.A., at 1-877-498-8861, and other information are posted on BD’s Four Seasons Hotel New York or by accessing the “Buy stock direct” website at www.bd.com/investors. 57 East 57th Street feature located within the Investor New York, NY 10022 Centre of Computershare’s website Shareholders may receive, without This annual report is not a at www.computershare.com. charge, printed copies of these solicitation of proxies. documents, including BD’s 2015 NYSE SYMBOL: BDX Annual Report on Form 10-K, TRANSFER AGENT AND REGISTRAR including the financial statements Computershare Trust Company, N.A. INDEPENDENT AUDITORS and related schedules, by contacting: 250 Royall Street Ernst & Young LLP Canton, MA 02021 5 Times Square Investor Relations Phone: 1-877-498-8861 New York, NY 10036-6530 BD International: 1-781-575-2726 Phone: 1-212-773-3000 1 Becton Drive Internet: www.computershare.com Internet: www.ey.com Franklin Lakes, NJ 07417-1880 Phone: 1-800-284-6845 DIRECT STOCK PURCHASE PLAN SHAREHOLDER INFORMATION Internet: www.bd.com The Direct Stock Purchase Plan At November 30, 2015, BD had The trademarks indicated by italics are established through Computershare 14,414 shareholders of record. BD’s property of Becton, Dickinson and Company, Trust Company, N.A., enhances the Statement of Corporate Governance its subsidiaries or related companies. services provided to existing shareholders ©2015 BD Principles, BD’s Code of Conduct, the and facilitates initial investments in charters of BD’s Committees of the All other brands or logos represented herein BD shares. Plan documentation and Board of Directors, BD’s reports and are trademarks of their respective owners. additional information may be obtained statements filed with or furnished to the

The graph below presents a comparison of cumulative total return to shareholders for the five-year period ended September 30, 2015, for BD, the S&P 500 Index and the S&P 500 Health Care Equipment Index.

Cumulative total return to shareholders is measured by dividing total dividends (assuming dividend reinvestment) plus per share price change for the period by the share price at the beginning of the measurement period. BD’s cumulative shareholder return is based on an investment of $100 on September 30, 2010, and is compared to the cumulative total return of the S&P 500 Index and the S&P 500 Health Care Equipment Index over the same period with a like amount invested.

Comparison of 5-year Cumulative Total Return Among Becton, Dickinson and Company, the S&P 500 Index, and the S&P 500 Health Care Equipment Index*

Becton, Dickinson 200 and Company S&P 500 Health Care 175 Equipment Index S&P 500 Index 150 Dollars

125

100

Sept 2010 Sept 2011 Sept 2012 Sept 2013 Sept 2014 Sept 2015 *Source: Thomson Reuters

BD 2015 ANNUAL REPORT 6 7/ 7 Advancing the world of health CORPORATE OFFICERS

VINCENT A. FORLENZA JEROME V. HURWITZ PATTI E. RUSSELL Chairman, Chief Executive Officer Executive Vice President and Chief Human Senior Vice President and and President Resources Officer Chief Ethics and Compliance Officer

PIERRE BOISIER WILLIAM A. KOZY ANTOINETTE F. SEGRETO Executive Vice President and Executive Vice President and Chief Senior Vice President — Taxes Chief Quality Officer Operating Officer NABIL SHABSHAB GARY M. COHEN JAMES LIM Executive Vice President — Strategic Executive Vice President and President — Executive Vice President and President — Planning and Chief Marketing Officer Global Health Greater Asia JEFFREY S. SHERMAN ALEXANDRE CONROY RICHARD J. NAPLES Executive Vice President and Executive Vice President and President — Executive Vice President and General Counsel Europe, EMA and Americas Chief Regulatory Officer STEPHEN SICHAK, JR. GARY DEFAZIO THOMAS POLEN Executive Vice President and Chief Senior Vice President and Executive Vice President and Integrated Supply Chain Officer Corporate Secretary President — Medical Segment ELLEN R. STRAHLMAN, M.D. JOHN E. GALLAGHER CHRISTOPHER R. REIDY Executive Vice President — Research and Senior Vice President, Corporate Finance, Executive Vice President, Chief Financial Development and Chief Medical Officer Treasurer and Controller Officer and Chief Administrative Officer LINDA THARBY DAVID W. HIGHET Executive Vice President and President — Senior Vice President, Chief Intellectual Life Sciences Segment Property Counsel and Assistant Secretary

BOARD OF DIRECTORS

BASIL L. ANDERSON 1,2,4 CHRISTOPHER JONES 1,4,5 CLAIRE POMEROY, M.D. 3,5 Retired Vice Chairman — Staples, Inc. Retired Chief Executive Officer — President — The Albert and Mary JWT Worldwide Lasker Foundation HENRY P. BECTON, JR. 3,4,5 Vice Chairman and Former President — MARSHALL O. LARSEN 2,3,4 REBECCA W. RIMEL 1,5 WGBH Foundation Retired Chairman, President and Chief President and Chief Executive Officer — Executive Officer — Goodrich Corporation The Pew Charitable Trusts CATHERINE M. BURZIK 1,5 Former President and Chief Executive GARY A. MECKLENBURG 2,3 BERTRAM L. SCOTT 1,2 Officer — Kinetic Concepts, Inc. Retired President and Chief Executive Senior Vice President of Population Officer — Northwestern Memorial Health — Novant Health EDWARD F. DEGRAAN 2,3 HealthCare Retired Vice Chairman — Gillette of the Procter & Gamble Company JAMES F. ORR 2,3 Committees appointed by the Board Retired Chairman and Chief Executive of Directors 4 VINCENT A. FORLENZA Officer — Convergys Corporation 1 Audit Committee Chairman, Chief Executive Officer 2 Compensation and Management and President WILLARD J. OVERLOCK, JR. 1,4,5 Development Committee Retired Partner — Goldman, Sachs & 3 Corporate Governance and CLAIRE M. FRASER, PH.D. 3,5 Company Nominating Committee Director — Institute for Genome Sciences, 4 Executive Committee University of Maryland School of Medicine 5 Science, Marketing, Innovation and Technology Committee

BD 2015 ANNUAL REPORT 8 Advancing the world of health The New BD — structured to serve customers with unique solutions

ChloraPrep® Skin Antiseptic

Pen Needle PROVIDE companies

Respiratory CUSTOMERS SERVING effective and DELIVERING OUTCOMES DELIVERING Solutions OFFERINGSINNOVATIVE Consumers BD Hypak™ Glass safe medication Prefillable Syringes management

BUSINESSES Academic and Cytometer Near-Patient CD4 Counter ENHANCE government infectious institutions BD Horizon Brilliant™

disease CUSTOMERS SERVING

GATEFOLD - 8.5 x 11.25 IFC BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and OUR PURPOSE: evolving health needs. Advancing the world of health

MORE THAN OUR FOCUS:

ENABLING safer, simpler and more effective drug delivery

45,000 IMPROVING outcomes ASSOCIATES SERVING through more accurate, timely and efficient diagnostics

FRONT COVER - 8.75 x 11.25 GATEFOLD - 8.5 x 11.25 Design by Addison www.addison.com Addison by Design

members of the Paper Task Force. Task Paper the of members

other and Fund Defense Environmental

by research on based Calculations Source: *

energy not consumed not energy please visit www.bd.com/sustainability2014. visit please

11,500,000 BTUs 11,500,000

Program and our 2020 Sustainability Goals, Goals, Sustainability 2020 our and Program

For information about BD’s Sustainability Sustainability BD’s about information For

greenhouse gases prevented gases greenhouse

22,181 lbs net lbs 22,181

certified renewable energy certificates. energy renewable certified Green-e

manufactured with electricity that is offset with with offset is that electricity with manufactured

solid waste not generated not waste solid

and and is designated Ancient Forest Friendly Forest Ancient designated is

8,053 lbs 8,053 TM

an average of 100% post-consumer waste. It It waste. post-consumer 100% of average an

with an average of 100% recycled fiber and and fiber recycled 100% of average an with wastewater flow saved flow wastewater

120,300 gal 120,300 25,736 pounds of Reincarnation Silk 100, made made 100, Silk Reincarnation of pounds 25,736

BD saved the following resources by using using by resources following the saved BD

trees preserved for the future the for preserved trees

258 PRINTING INFORMATION* PRINTING